NYSE:BMYPharmaceuticals
Bristol Myers Squibb (BMY) Stock Still Looks Cheap After Fresh AI Drug Discovery News
Bristol-Myers Squibb stock has delivered a strong 42.2% return over the past year, while the current valuation checks show a mixed picture and the Discounted Cash Flow (DCF) intrinsic value estimate points to the shares trading at a sizeable discount to that model.
The 42.2% one year return sets a high bar for new buyers, since a lot of optimism can already be reflected in the current share price.
The expanded use of Nvidia powered AI systems for drug discovery may support expectations for...